Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667656 | 0.97 | DPP4 (0.90) | DPP4CYP3A4 | |
| SCHEMBL4668939 | 0.97 | DPP4 (0.90) | DPP4CYP3A4 | |
| SCHEMBL8364873 | 0.93 | DPP4 (0.83) | DPP4CYP3A4 | |
| SCHEMBL4668849 | 0.92 | DPP4 (0.81) | DPP4 | |
| SCHEMBL4668943 | 0.92 | DPP4 (0.81) | DPP4CYP3A4 | |
| SCHEMBL4668947 | 0.92 | DPP4 (0.81) | DPP4CYP3A4 | |
| SCHEMBL556850 | 0.92 | DPP4 (0.84) | DPP4CYP3A4 | |
| SCHEMBL555347 | 0.91 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL4667775 | 0.91 | DPP4 (1.00) | DPP4CYP3A4 | |
| SCHEMBL196162 | 0.91 | DPP4 (0.83) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232281-B2 | Uses of DPP-IV inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120165251-A1 | Diabetes therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120122776-A1 | DPP-IV INHIBITORS FOR TREATMENT OF DIABETES IN PEDIATRIC PATIENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120094894-A1 | ANTIDIABETIC MEDICATIONS COMPRISING A DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONALLY IN COMBINATION WITH OTHER ANTIDIABETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110301182-A1 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110275561-A1 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110092510-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110065731-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2023902-B1 | DPP IV INHIBITOR FORMULATIONS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275561-A1 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 129/4885 |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | DPP4, SLC5A1, DPP7 | DPP4 1/4885CYP3A4 48/4885 |
| US-20120094894-A1 | ANTIDIABETIC MEDICATIONS COMPRISING A DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONALLY IN COMBINATION WITH OTHER ANTIDIABETICS | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 54/4885 |
| US-20110092510-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 90/4885 |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 179/4885 |
| US-20120165251-A1 | Diabetes therapy | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 108/4885 |
| US-20110065731-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 179/4885 |
| US-20110301182-A1 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 320/4885 |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | DPP4 2/4885CYP3A4 1095/4885 |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885CYP3A4 279/4885 |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 3420/4885 |
| US-20120122776-A1 | DPP-IV INHIBITORS FOR TREATMENT OF DIABETES IN PEDIATRIC PATIENTS | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.